Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

Phase 2

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Avenciguat
Drug: Placebo

First Posted Date: 2021-02-03

Last Posted Date: 2024-05-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 261

Registration Number: NCT04736628

Locations: 🇺🇸
Research by Design, LLC, Chicago, Illinois, United States
🇺🇸
Homestead Associates in Research, Miami, Florida, United States
🇺🇸
Nevada Kidney Disease and Hypertension Centers, PLLC, Las Vegas, Nevada, United States

and more 106 locations

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 474121 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 474121
Drug: Itraconazole

First Posted Date: 2021-01-20

Last Posted Date: 2024-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT04716894

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 706321 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 706321
Drug: Itraconazole

First Posted Date: 2021-01-19

Last Posted Date: 2021-05-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT04714073

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease (ILD) With a Progressive Phenotype in Everyday Clinical Practice: a Real-world Evaluation

Completed

Conditions: Lung Diseases, Interstitial

Interventions: Drug: Nintedanib

First Posted Date: 2021-01-11

Last Posted Date: 2025-04-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 108

Registration Number: NCT04702893

Locations: 🇩🇪
Universitätsklinikum Aachen, AöR, Aachen, Germany
🇩🇪
Pneumologische Praxis Dr. Löh, Bad Homburg, Germany
🇩🇪
Vivantes Klinikum Neukölln, Berlin, Germany

and more 18 locations

A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic Arthritis

Phase 2

Withdrawn

Conditions: Arthritis, Psoriatic

Interventions: Drug: BI 730357
Drug: Placebo

First Posted Date: 2020-12-23

Last Posted Date: 2021-11-08

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT04680676

A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Percoffedrinol®
Drug: Coumadin®
Drug: Antra MUPS®
Drug: Midazolam-ratiopharm®
Drug: BI 730357

First Posted Date: 2020-12-22

Last Posted Date: 2023-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT04679948

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium bromide plus Olodaterol

First Posted Date: 2020-12-17

Last Posted Date: 2024-06-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1396

Registration Number: NCT04672941

Locations: 🇬🇷
Metropolitan Hospitsal, PNOI Pulmonology Clinic, Athens, Greece
🇬🇷
European Interbalkan Medical Center, Pulmonology Clinic, Thessaloniki, Greece

A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: 10 milligram (mg) BI 474121
Drug: 40 milligram (mg) BI 474121
Drug: 2.5 milligram (mg) BI 474121
Drug: 20 milligram (mg) BI 474121

First Posted Date: 2020-12-17

Last Posted Date: 2024-03-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT04672954

Locations: 🇳🇱
Centre Human Drug Research, Leiden, Netherlands

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: Placebo
Drug: BI 456906

First Posted Date: 2020-12-14

Last Posted Date: 2023-11-02

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 387

Registration Number: NCT04667377

Locations: 🇺🇸
Valley Weight Loss Clinic, Fargo, North Dakota, United States
🇦🇺
Nepean Hospital, Kingswood, New South Wales, Australia
🇺🇸
Lucas Research, Inc., Morehead City, North Carolina, United States

and more 40 locations

A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are Tolerated

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 764198
Drug: Placebo

First Posted Date: 2020-12-14

Last Posted Date: 2021-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 44

Registration Number: NCT04665700

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy